109 filings
Page 3 of 6
CORRESP
cyq1e6h06qfigcy
11 Aug 22
Correspondence with SEC
12:00am
8-K
flq7rrn6u
3 Aug 22
Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial
8:30am
8-K
1bpzmev j1pxgo
21 Jun 22
Departure of Directors or Certain Officers
4:20pm
8-K
k1ubyr 0fn7lqgc8qy
17 Jun 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
wsc sh4ue7
13 Jun 22
Submission of Matters to a Vote of Security Holders
8:30am
8-K
wo8rq864bj1x 3w
19 May 22
Departure of Directors or Certain Officers
4:18pm
CORRESP
y11ptn5jkl2zl
18 May 22
Correspondence with SEC
12:00am
CORRESP
gcxg3j2yazde6ripxpn9
16 May 22
Correspondence with SEC
12:00am
8-K
7fta41xye1 sedv
12 May 22
Landos Biopharma Reports First Quarter 2022 Results and Provides Business Update
4:21pm
DEFA14A
ye9dm
28 Apr 22
Additional proxy soliciting materials
4:20pm
DEF 14A
31rs6 fdt6x
28 Apr 22
Definitive proxy
4:16pm
8-K
gmsivwb
26 Apr 22
Departure of Directors or Certain Officers
4:16pm
8-K
2wihs73
6 Apr 22
Departure of Directors or Certain Officers
4:20pm
UPLOAD
xvr40hzly0s
30 Mar 22
Letter from SEC
12:00am
S-3
e095s dl5reg
24 Mar 22
Shelf registration
5:26pm
S-8
zjapjeyhu dg4g7c
24 Mar 22
Registration of securities for employees
5:21pm
8-K
muz5ojvq46mkgxxa6rb
24 Mar 22
Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update
5:00pm
8-K
74tc1
10 Mar 22
Landos Biopharma Appoints Roger Adsett to its Board of Directors
8:20am